{
  "retracted": false,
  "timestamp": 1590969600000,
  "updates": [
    {
      "timestamp": 1592624448148,
      "identifier": {
        "doi": "10.1016/j.msard.2020.102107"
      },
      "type": "erratum"
    }
  ],
  "identifier": {
    "doi": "10.1016/j.msard.2019.101498"
  },
  "journal": "Multiple Sclerosis and Related Disorders",
  "publisher": "Elsevier BV",
  "title": "Corrigendum to “Risk factors for reactivation of clinical disease activity in multiple sclerosis after natalizumab cessation” [Multiple Sclerosis and Related Disorders 38 (2020) 101498]"
}
